Zoladex (Goserelin) is indicated in the palliative treatment of advanced carcinoma of the prostate. Zoladex (Goserelin) is also indicated for use in combination with flutamide for the management of locally confined Stage T2b-T4 (Stage B2-C) carcinoma of the prostate. Treatment with the combination should start 8 weeks prior to initiating radiation therapy and continue during radiation therapy.
The most common Zoladex side effects (incidence >5% in clinical trials) for ZOLADEX 3.6-mg depot: hot flashes (62%), sexual dysfunction (21%), decreased erections (18%), lower urinary tract symptoms (13%), lethargy (8%), pain (worsened in the first 30 days) (8%), edema (7%), upper respiratory infection (7%), rash (6%), and sweating (6%).